Anne Louise Grønnemose

ORCID: 0000-0003-4583-8010
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lipid metabolism and disorders
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Parkinson's Disease Mechanisms and Treatments
  • Alzheimer's disease research and treatments
  • Peptidase Inhibition and Analysis
  • Protease and Inhibitor Mechanisms
  • Conducting polymers and applications
  • S100 Proteins and Annexins
  • Caveolin-1 and cellular processes
  • Metabolism, Diabetes, and Cancer
  • Ginkgo biloba and Cashew Applications
  • Biochemical and biochemical processes
  • Neurological disorders and treatments

University of Southern Denmark
2021-2023

University of Copenhagen
2021-2023

Rigshospitalet
2021-2023

Copenhagen University Hospital
2023

Aarhus University
2021-2022

The lipolytic processing of triglyceride-rich lipoproteins (TRLs) by lipoprotein lipase (LPL) is crucial for the delivery dietary lipids to heart, skeletal muscle, and adipose tissue. TRLs LPL regulated in a tissue-specific manner complex interplay between activators inhibitors. Angiopoietin-like protein 4 (ANGPTL4) inhibits reducing its thermal stability catalyzing irreversible unfolding LPL's α/β-hydrolase domain. We previously mapped ANGPTL4 binding site on defined downstream events...

10.1073/pnas.2221888120 article EN cc-by-nc-nd Proceedings of the National Academy of Sciences 2023-04-24

GPIHBP1, an endothelial cell (EC) protein, captures lipoprotein lipase (LPL) within the interstitial spaces (where it is secreted by myocytes and adipocytes) transports across ECs to its site of action in capillary lumen. GPIHBP1's 3-fingered LU domain required for LPL binding, but function acidic (AD) has remained unclear. We created mutant mice lacking AD found severe hypertriglyceridemia. As expected, GPIHBP1 retained capacity bind LPL. Unexpectedly, however, most was located on abluminal...

10.1172/jci157500 article EN cc-by Journal of Clinical Investigation 2022-02-28

α-Synuclein (α-Syn) is an intrinsically disordered protein which self-assembles into highly organized β-sheet structures that accumulate in plaques brains of Parkinson's disease patients. Oxidative stress influences α-Syn structure and self-assembly; however, the basis for this remains unclear. Here we characterize chemical physical effects mild oxidation on monomeric its aggregation. Using a combination biophysical methods, small-angle X-ray scattering, native ion mobility mass...

10.1021/jacs.2c03607 article EN cc-by Journal of the American Chemical Society 2022-06-24

The aggregation of α-synuclein (αSN) and increased oxidative stress leading to lipid peroxidation are pathological characteristics Parkinson's disease (PD). Here, we report that αSN in the presence products 4-hydroxy-2-nonenal (HNE) 4-oxo-2-nonenal (ONE) increases stability yield oligomers (αSO). Further, show ONE is more efficient than HNE at inducing αSO. In addition, demonstrate two αSO differ both size shape. ONE-αSO smaller HNE-αSO, except when they formed a high molar excess aldehyde....

10.1021/acs.biochem.1c00478 article EN Biochemistry 2021-11-03

Oligomers of the protein α-synuclein (α-syn) are thought to be a major toxic species in Parkinson's disease, particularly through their ability permeabilize cell membranes. The green tea polyphenol epigallocatechin gallate (EGCG) has been found reduce this ability. We have analyzed α-syn oligomer dynamics and interconversion by H/D exchange monitored mass spectrometry (HDX-MS). Our results show that two oligomers OI OII co-exist equilibrium; is multimer its dissociation can followed HDX-MS...

10.1016/j.jmb.2022.167855 article EN cc-by Journal of Molecular Biology 2022-10-12

A comprehensive literature reports on the correlation between elevated levels of urokinase-type plasminogen activator receptor (uPAR) and severity diseases with chronic inflammation including solid cancers. Molecular imaging is widely used as a non-invasive method to locate disease dissemination via full body scans stratify patients for targeted treatment. To date, only probe targeting uPAR that has reached clinical phase-II testing relies high-affinity 9-mer peptide (AE105), several studies...

10.1038/s41598-023-43934-w article EN cc-by Scientific Reports 2023-10-11
Coming Soon ...